Teva FDA Friday, March 10, 2023 +0.20 Positive

FDA Approves TOPIRAMATE — Teva Pharmaceuticals, Inc.

Teva Pharmaceuticals announced on March 10, 2023, the FDA approval of its generic version of FDA-approved with its High Blood Pressure drugs (HBP) and epilepsy. This approval allows Teva to enter a lucrative market, further strengthening its generics portfolio amidst ongoing industry competitiveness.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed